119 related articles for article (PubMed ID: 38441546)
21. IMP3 accelerates the progression of prostate cancer through inhibiting PTEN expression in a SMURF1-dependent way.
Zhang X; Wang D; Liu B; Jin X; Wang X; Pan J; Tu W; Shao Y
J Exp Clin Cancer Res; 2020 Sep; 39(1):190. PubMed ID: 32938489
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA‑766 inhibits papillary thyroid cancer progression by directly targeting insulin receptor substrate 2 and regulating the PI3K/Akt pathway.
Zhao J; Li Z; Chen Y; Zhang S; Guo L; Gao B; Jiang Y; Tian W; Hao S; Zhang X
Int J Oncol; 2019 Jan; 54(1):315-325. PubMed ID: 30387841
[TBL] [Abstract][Full Text] [Related]
23. CHIP promotes thyroid cancer proliferation via activation of the MAPK and AKT pathways.
Zhang L; Liu L; He X; Shen Y; Liu X; Wei J; Yu F; Tian J
Biochem Biophys Res Commun; 2016 Aug; 477(3):356-62. PubMed ID: 27342662
[TBL] [Abstract][Full Text] [Related]
24. GSG2 promotes tumor growth through regulating cell proliferation in hepatocellular carcinoma.
Li L; Li S; Wang H; Li L; Wang P; Shen D; Dang X
Biochem Biophys Res Commun; 2022 Oct; 625():109-115. PubMed ID: 35952607
[TBL] [Abstract][Full Text] [Related]
25. SKP2 Contributes to AKT Activation by Ubiquitination Degradation of PHLPP1, Impedes Autophagy, and Facilitates the Survival of Thyroid Carcinoma.
Shao Y; Ren W; Dai H; Yang F; Li X; Zhang S; Liu J; Yao X; Zhao Q; Sun X; Zheng Z; Xu C
Mol Cells; 2023 Jun; 46(6):360-373. PubMed ID: 36694914
[TBL] [Abstract][Full Text] [Related]
26. Long noncoding RNA CASC9 promotes the proliferation and metastasis of papillary thyroid cancer via sponging miR-488-3p.
Chen Y; Li Y; Gao H
Cancer Med; 2020 Mar; 9(5):1830-1841. PubMed ID: 31943867
[TBL] [Abstract][Full Text] [Related]
27. TRIM29 promotes progression of thyroid carcinoma via activating P13K/AKT signaling pathway.
Xu J; Li Z; Su Q; Zhao J; Ma J
Oncol Rep; 2017 Mar; 37(3):1555-1564. PubMed ID: 28098872
[TBL] [Abstract][Full Text] [Related]
28. A tumor-suppressing role of TSPYL2 in thyroid cancer: Through interacting with SIRT1 and repressing SIRT1/AKT pathway.
Zhang X; Wu X; Yao W; Wang YH
Exp Cell Res; 2023 Nov; 432(1):113777. PubMed ID: 37696385
[TBL] [Abstract][Full Text] [Related]
29. FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma.
Bellelli R; Castellone MD; Garcia-Rostan G; Ugolini C; Nucera C; Sadow PM; Nappi TC; Salerno P; Cantisani MC; Basolo F; Gago TA; Salvatore G; Santoro M
Endocr Relat Cancer; 2012 Oct; 19(5):695-710. PubMed ID: 22919068
[TBL] [Abstract][Full Text] [Related]
30. HPIP promotes thyroid cancer cell growth, migration and EMT through activating PI3K/AKT signaling pathway.
Wang SC; Chai DS; Chen CB; Wang ZY; Wang L
Biomed Pharmacother; 2015 Oct; 75():33-9. PubMed ID: 26463629
[TBL] [Abstract][Full Text] [Related]
31. Metallothionein 1G functions as a tumor suppressor in thyroid cancer through modulating the PI3K/Akt signaling pathway.
Fu J; Lv H; Guan H; Ma X; Ji M; He N; Shi B; Hou P
BMC Cancer; 2013 Oct; 13():462. PubMed ID: 24098937
[TBL] [Abstract][Full Text] [Related]
32. GSG2 (Haspin) promotes development and progression of bladder cancer through targeting KIF15 (Kinase-12).
Chen Y; Fu D; Zhao H; Cheng W; Xu F
Aging (Albany NY); 2020 May; 12(10):8858-8879. PubMed ID: 32439830
[TBL] [Abstract][Full Text] [Related]
33. MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway.
Ma Y; Qin H; Cui Y
Biochem Biophys Res Commun; 2013 Nov; 441(4):958-63. PubMed ID: 24220341
[TBL] [Abstract][Full Text] [Related]
34. miR-17-5p knockdown inhibits proliferation, autophagy and promotes apoptosis in thyroid cancer via targeting PTEN.
Shi YP; Liu GL; Li S; Liu XL
Neoplasma; 2020 Mar; 67(2):249-258. PubMed ID: 31973533
[TBL] [Abstract][Full Text] [Related]
35. CDK5RAP3 acts as a putative tumor inhibitor in papillary thyroid carcinoma via modulation of Akt/GSK-3β/Wnt/β-catenin signaling.
Feng X; Jiang J; Sun L; Zhou Q
Toxicol Appl Pharmacol; 2022 Apr; 440():115940. PubMed ID: 35219640
[TBL] [Abstract][Full Text] [Related]
36. CRLF1 promotes malignant phenotypes of papillary thyroid carcinoma by activating the MAPK/ERK and PI3K/AKT pathways.
Yu ST; Zhong Q; Chen RH; Han P; Li SB; Zhang H; Yuan L; Xia TL; Zeng MS; Huang XM
Cell Death Dis; 2018 Mar; 9(3):371. PubMed ID: 29515111
[TBL] [Abstract][Full Text] [Related]
37. High Expression of
Wang X; Bi Y; Liu X; Liu L; Hao M; Tian M; Shang J
Cancer Biother Radiopharm; 2022 May; 37(4):313-323. PubMed ID: 34388030
[No Abstract] [Full Text] [Related]
38. MiR-1246 regulates the PI3K/AKT signaling pathway by targeting PIK3AP1 and inhibits thyroid cancer cell proliferation and tumor growth.
Li J; Zhang Z; Hu J; Wan X; Huang W; Zhang H; Jiang N
Mol Cell Biochem; 2022 Mar; 477(3):649-661. PubMed ID: 34870753
[TBL] [Abstract][Full Text] [Related]
39. Methylation-Mediated Silencing of ATF3 Promotes Thyroid Cancer Progression by Regulating Prognostic Genes in the MAPK and PI3K/AKT Pathways.
Xiao X; Chen M; Sang Y; Xue J; Jiang K; Chen Y; Zhang L; Yu S; Lv W; Li Y; Liu R; Xiao H
Thyroid; 2023 Dec; 33(12):1441-1454. PubMed ID: 37742107
[No Abstract] [Full Text] [Related]
40. LINC00641 impeded the malignant biological behaviors of papillary thyroid carcinoma cells via interacting with IGF2BP1 to reduce GLI1 mRNA stability.
Meng D; Zhao S; Wu L; Ma X; Zhao D; Li Z
Hum Exp Toxicol; 2023; 42():9603271231180856. PubMed ID: 37291850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
